AVI BioPharma Announces NEUGENE Antisense Collaboration With USAMRIID On Biodefense Agents
AVI BioPharma, Inc. (Nasdaq:AVII), today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The five-year agreement provides for testing of AVI's NEUGENE(R) antisense therapeutics against several viruses, bacteria and toxins that may be used as bioterror agents